MET and lung adenocarcinoma: MET exon 14 skipping mutations gained importance when Frampton et al. and Paik et al. first reported large studies that featured patients with stage IV lung adenocarcinomas harboring a variety of MET exon 14 splice variants, which resulted in MET exon 14 skipping and showed clinical sensitivity towards MET inhibitors [25,27].